Keisuke Kakisaka1, Yuji Suzuki2, Yudai Fujiwara2, Tamami Abe2, Miki Yonezawa2, Hidekatsu Kuroda2, Kazuyuki Ishida3, Tamotsu Sugai3, Yasuhiro Takikawa2. 1. Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate, 0208505, Japan. keikaki@iwate-med.ac.jp. 2. Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate, 0208505, Japan. 3. Department of Molecular Diagnostic Pathology, Iwate Medical University, Morioka, Japan.
Abstract
BACKGROUND: The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased. Non-alcoholic steatohepatitis (NASH) shows progression of liver fibrosis in NAFLD. It remains unclear which patients with NAFLD will show progression of liver fibrosis. Therefore, we aimed to investigate the risk factor associated with the progression of liver fibrosis among patients with NAFLD. METHODS: This observational study enrolled 157 patients with biopsy-proven NAFLD. Thirty-two patients were excluded because of lack of data. The accuracy of the formulae for estimating liver fibrosis, i.e., the FIB-4 index, APRI, and Forns index, was compared. Using serial changes of the best formula for liver fibrosis, we identified factors associated with the progression of liver fibrosis. Histological liver fibrosis was quantified using the Brunt stage. RESULTS: Sixty-three patients were diagnosed as having NASH. The FIB-4 index provided the best diagnostic accuracy for liver fibrosis [Brunt stage 0 versus 1-4, areas under the curve (AUC) 0.74; 0-1 versus 2-4, AUC 0.77; 0-2 versus 3-4, AUC 0.78; and 1-3 versus 4, AUC 0.87]. The association between body mass index, sex, observation period, and histological findings (liver fat content, bridging fibrosis, and hepatocyte ballooning) with the change in the FIB-4 index was evaluated among patients with NASH, using multivariate analysis. Among these factors, hepatocyte ballooning was associated with an increase in the FIB-4 index. CONCLUSION: The FIB-4 index was the best formula for estimating liver fibrosis in patients with biopsy-proven NAFLD, and the presence of ballooned hepatocytes was a risk factor for the progression of liver fibrosis.
BACKGROUND: The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased. Non-alcoholic steatohepatitis (NASH) shows progression of liver fibrosis in NAFLD. It remains unclear which patients with NAFLD will show progression of liver fibrosis. Therefore, we aimed to investigate the risk factor associated with the progression of liver fibrosis among patients with NAFLD. METHODS: This observational study enrolled 157 patients with biopsy-proven NAFLD. Thirty-two patients were excluded because of lack of data. The accuracy of the formulae for estimating liver fibrosis, i.e., the FIB-4 index, APRI, and Forns index, was compared. Using serial changes of the best formula for liver fibrosis, we identified factors associated with the progression of liver fibrosis. Histological liver fibrosis was quantified using the Brunt stage. RESULTS: Sixty-three patients were diagnosed as having NASH. The FIB-4 index provided the best diagnostic accuracy for liver fibrosis [Brunt stage 0 versus 1-4, areas under the curve (AUC) 0.74; 0-1 versus 2-4, AUC 0.77; 0-2 versus 3-4, AUC 0.78; and 1-3 versus 4, AUC 0.87]. The association between body mass index, sex, observation period, and histological findings (liver fat content, bridging fibrosis, and hepatocyte ballooning) with the change in the FIB-4 index was evaluated among patients with NASH, using multivariate analysis. Among these factors, hepatocyte ballooning was associated with an increase in the FIB-4 index. CONCLUSION: The FIB-4 index was the best formula for estimating liver fibrosis in patients with biopsy-proven NAFLD, and the presence of ballooned hepatocytes was a risk factor for the progression of liver fibrosis.
Authors: Siddharth Singh; Sudhakar K Venkatesh; Rohit Loomba; Zhen Wang; Claude Sirlin; Jun Chen; Meng Yin; Frank H Miller; Russell N Low; Tarek Hassanein; Edmund M Godfrey; Patrick Asbach; Mohammad Hassan Murad; David J Lomas; Jayant A Talwalkar; Richard L Ehman Journal: Eur Radiol Date: 2015-08-28 Impact factor: 5.315
Authors: Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick Journal: J Hepatol Date: 2010-06-25 Impact factor: 25.083
Authors: Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: Simona Bota; Harald Herkner; Ioan Sporea; Petra Salzl; Roxana Sirli; Adriana M Neghina; Markus Peck-Radosavljevic Journal: Liver Int Date: 2013-07-16 Impact factor: 5.828
Authors: Z M Younossi; T Gramlich; Y C Liu; C Matteoni; M Petrelli; J Goldblum; L Rybicki; A J McCullough Journal: Mod Pathol Date: 1998-06 Impact factor: 7.842
Authors: Nahum Méndez-Sánchez; Eira Cerda-Reyes; Fátima Higuera-de-la-Tijera; Ana K Salas-García; Samantha Cabrera-Palma; Guillermo Cabrera-Álvarez; Carlos Cortez-Hernández; Luis A Pérez-Arredondo; Emma Purón-González; Edgar Coronado-Alejandro; Arturo Panduro; Heriberto Rodríguez-Hernández; Vania C Cruz-Ramón; Alejandro Valencia-Rodríguez; Xingshun Qi; Nashla Hamdan-Pérez; Nancy E Aguilar-Olivos; Beatriz Barranco-Fragoso; Oscar Ramírez-Pérez; Alfonso Vera-Barajas Journal: F1000Res Date: 2020-01-28
Authors: Andrea D Coviello; Manal F Abdelmalek; Anastasia-Stefania Alexopoulos; Matthew J Crowley; Ying Wang; Cynthia A Moylan; Cynthia D Guy; Ricardo Henao; Dawn L Piercy; Keri A Seymour; Ranjan Sudan; Dana D Portenier; Anna Mae Diehl Journal: Hepatology Date: 2021-06-02 Impact factor: 17.425